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http://dx.doi.org/10.1016/j.ccr.2014.07.025SUMMARYMore thanhalf of humancancershaveaberrantly upregulatedphosphoinositide signals; yet howphospholipid
signals are controlled during tumorigenesis is not fully understood. We report here that TIPE3 (TNFAIP8L3) is
the transfer protein of phosphoinositide second messengers that promote cancer. High-resolution crystal
structure of TIPE3 shows a large hydrophobic cavity that is occupied by a phospholipid-like molecule.
TIPE3 preferentially captures and shuttles two lipid second messengers, i.e., phosphatidylinositol 4,5-
bisphosphate and phosphatidylinositol 3,4,5-trisphosphate, and increases their levels in the plasma mem-
brane.Notably, humancancers havemarkedly upregulatedTIPE3expression. Knockingout TIPE3diminishes
tumorigenesis, whereas enforced TIPE3 expression enhances it in vivo. Thus, the function andmetabolism of
phosphoinositide second messengers are controlled by a specific transfer protein during tumorigenesis.INTRODUCTION
Tumorigenesis is a multistep process orchestrated by several
classes of molecules that control cell death and/or growth. The
TNFAIP8 (tumor necrosis factor-alpha-induced protein 8, or
TIPE) family of proteins has been recently described as regula-
tors of tumorigenesis and inflammation (Kumar et al., 2004;
Sun et al., 2008). TNFAIP8 promotes tumor metastasis and is
a risk factor for non-Hodgkin’s lymphoma in humans and for
bacterial infection in mice (Ahn et al., 2010; Zhang et al., 2012).
Similarly, TIPE2 (TNFAIP8L2) regulates both carcinogenesis
and inflammation, and its germline deletion leads to fatal inflam-
matory diseases (Gus-Brautbar et al., 2012; Sun et al., 2008;
Wang et al., 2012). TIPE1 has been reported to regulate cell
death (Hitomi et al., 2008), whereas the role of TIPE3 has not
yet been described. How TNFAIP8 family regulates tumorigen-
esis is largely unknown.Significance
More than half of human cancers have aberrantly upregulated p
in cancer cells is not fully understood. The TNFAIP8 family of pr
cancer, although its mechanisms of action are largely unknown
tein of two lipid second messengers, PtdIns(4,5)P2 and PtdIns
transformation. This finding explains why normal cells can cont
nomenon widely recognized but poorly understood. Therefore
nant diseases.
CPhosphoinositides constitute approximately 1%of lipids in the
eukaryotic plasma membrane, but they play a major role as
signaling molecules in both normal and tumor cells. There are
seven phosphoinositides, which are generated by phosphoryla-
tion of the inositol ring of phosphatidylinositol (PtdIns) on the
third, fourth, and/or fifth hydroxyl groups (Fruman et al., 1998).
PtdIns 4,5-bisphosphate (PtdIns(4,5)P2) plays key signaling roles
(Kwiatkowska and Sobota, 1999; McLaughlin et al., 2002). It is
the precursor of at least three second messengers: inositol
1,4,5-trisphosphate (Ins(1,4,5)P3) and diacylglycerol generated
through hydrolysis by phospholipase C (PLC) isoforms; and
PtdIns(3,4,5)P3 generated through phosphorylation by phos-
phoinositide-3 kinases (PI3Ks). More than half of human cancers
have aberrantly upregulated PtdIns(3,4,5)P3 or PtdIns(4,5)P2 sig-
nals. While somatic mutations of PTEN, Ras, and the a catalytic
subunit of PI3K (PIK3CA) account for many cases of the phos-
phoinositide signaling upregulation, other mechanisms of thehosphoinositide signals; yet how lipid signals are controlled
oteins has been recently described as a risk factor for human
. We report here that TIPE3 (TNFAIP8L3) is the transfer pro-
(3,4,5)P3, and is hijacked by cancer cells to cause malignant
rol their phospholipid signals but cancer cells cannot, a phe-
, TIPE3 may represent a therapeutic target for treating malig-
ancer Cell 26, 465–478, October 13, 2014 ª2014 Elsevier Inc. 465
0 
1 
2 
3 
0 
10 
20 
30 
40 
TI
P
E
3 
R
N
A MEF, PDGF 
Tumor                  Adjacent tissue 
A
F 
G 
0 
5 
10 
15 
20 
25 
shTIPE3 
shScr 
C
el
l n
um
be
r, 
10
5 
** 
** 
** 
0 
5 
10 
15 
20 
shTIPE3 
shScr 
C
el
l n
um
be
r, 
10
5 
** 
** 
* 
0 
0.5 
1 
1.5 
** 
0 
0.5 
1 
1.5 
N
um
be
r o
f c
ol
on
ie
s 
** 
0 
0.5 
1 
1.5 
N
um
be
r o
f c
ol
on
ie
s 
** 
TI
P
E
3
R
N
A NIH3T3, PDGF 
NCI-
H727 
T24 HT-29 
NCI-
H727 
T24 HT-29 
0 
1 
2 
3 
4 
5 
6 
shScr 
C
el
l n
um
be
r, 
10
6 
** 
** 
E
so
ph
ag
us
   
Lu
ng
 
Tumor                  Adjacent tissue 
Tumor Adjacent tissue 
p < 0.001 
TI
P
E
3 
ex
pr
es
si
on
 s
co
re
 10 
0 
2 
4 
6 
8 
Tumor Adjacent tissue 
p < 0.001 10 
0 
2 
4 
6 
8 
TI
P
E
3 
ex
pr
es
si
on
 s
co
re
 
N
um
be
r o
f c
ol
on
ie
s 
B C
D E
(legend on next page)
Cancer Cell
TIPE3 in Phospholipid Signaling and Cancer
466 Cancer Cell 26, 465–478, October 13, 2014 ª2014 Elsevier Inc.
Cancer Cell
TIPE3 in Phospholipid Signaling and Cancerdysregulation are being discovered as well (Vivanco and Saw-
yers, 2002; Yuan and Cantley, 2008). In this report, we describe
a mammalian transfer protein for PtdIns(4,5)P2 and PtdIns(3,4,5)
P3 and examine its role in phosphoinositide signaling.
RESULTS
TIPE3 Is Markedly Upregulated in Four Types of Human
Cancers and in Cells Treated with Growth Factors
TIPE3 is expressed in a wide range of organs, but its expression
levels vary greatly (Figure S1A available online). High levels of
TIPE3 messenger RNA (mRNA) were detected in murine uterus
and developing embryos, whereas little or no TIPE3 was de-
tected in lymphoid organs. Moderate expression of TIPE3 was
observed in many organs, including intestine, lung, brain,
bladder, and colon (Figure S1A). Similarly, murine and human
cell lines have varying levels of TIPE3 expression (Figures S1B
and S1C). It is interesting that, when treated with platelet-derived
growth factor (PDGF), serum-starved NIH 3T3 cells and primary
murine embryonic fibroblasts (MEFs) both markedly upregulated
TIPE3 expression in a time-dependent manner (Figure 1A).
To determine TIPE3 expression in human tumors, we studied,
by immunohistochemistry, tumor samples from 60 lung cancer
patients and 24 esophageal cancer patients. Marked upregula-
tion of TIPE3 protein was observed in the majority of tumor sec-
tions compared with adjacent nontumor sections from the same
patients (Figures 1B–1E; Figures S1D and S1E). Additionally, we
also detected significant TIPE3 upregulation in human cervical
cancer (70 patients) and colonadenocarcinoma (82 patients)
(data not shown). These results indicate that, similar to other
TIPE proteins, TIPE3 may be involved in tumorigenesis.
Overexpressing TIPE3 Promotes Tumorigenesis,
whereas Knocking out TIPE3 Inhibits It
To explore the potential role of TIPE3 in tumorigenesis, we used
knockdown, knockout, and overexpression approaches. Trans-
fection with a short hairpin RNA (shRNA) that targets TIPE3
(shTIPE3) significantly reduced TIPE3 expression in three human
cancer cell lines: NCI-H727 lung carcinoma cells (with KRasV12
and PIK3CAE545 mutations), T24 bladder carcinoma cells (with
HRasV12mutation), and HT-29 colorectal adenocarcinoma cells
(with PIK3CAT449 and BRAFV600E mutations) (Figures S1F and
S1G). This was associated with significant reduction in total cell
numbers (Figure 1F) and compromised ability of the cells to form
colonies in soft agar (Figure 1G). Conversely, when overex-
pressed, TIPE3 significantly increased the numbers of 293T cellsFigure 1. Upregulation of TIPE3 Expression Correlates with Tumorigen
(A) RT-PCR analyses of TIPE3 mRNA levels in the NIH 3T3 fibroblast cell line (lef
stimulated with 20 (left) and 50 (right) ng/ml of PDGF for the indicated times before
(right) and MEF (left) at 0 hr were set as 1.
(B–E) TIPE3 upregulation in human cancers. Immunohistochemistry analyses o
patients diagnosed with lung cancer (B and C) and esophageal cancer (D and E)
expression in tumors and adjacent tissues of 60 patients with lung cancer (C)
Supplemental Experimental Procedures. Each data point represents a TIPE3 exp
(F) Cell growth analysis of human NCI-H727, T24, and HT-29 cells stably expres
indicated times.
(G) Soft agar colony formation of NCI-H727, T24, and HT-29 cells expressing eithe
set as 1.
For (A), (F), and (G), values represent means ± SD. *p < 0.05; **p < 0.01. The experim
Cwith HRasV12 or PIK3CAE545 mutation (Figure S2A) and of
HRasV12-transformed NIH 3T3 cells (NIH 3T3-HRasV12) (Fig-
ure 2A). TIPE3 overexpression also increased the size of the col-
onies formed in soft agar (Figures 2B and S2B) and accelerated
cell cycle progression as evidenced by a reduced population
of G0/G1 cells and increased S/G2/M cells (Figure 2C). These
results indicate that TIPE3 promotes tumor cell growth in vitro.
To examine the effect of TIPE3 on tumorigenesis in vivo, we
first injected NIH 3T3-HRasV12 cells with or without TIPE3 over-
expression into nude mice (nu/nu). Strikingly, both tumor onset
and tumor growth were significantly accelerated in the TIPE3
group (Figure 2D). By day 10 following tumor cell injection, tu-
mors of the TIPE3 group were twice as large as those of the con-
trol group (p < 0.05, n = 14) (Figures 2E and S2C). The difference
in tumor size wasmost likely due to enhanced proliferation of the
TIPE3-overexpressing cells because increased bromodeoxyuri-
dine (BrdU) incorporation was observed in tumor sections of
the TIPE3 group (Figures 2F and S2D). Cell death, as determined
by cleaved (active) caspase-3 staining, may also play a role
because 0.86% cells in TIPE3-transfected tumors underwent
cell death compared to 1.94% cells in the control tumors
(Figure S2E).
Next, we studied carcinogen-induced tumorigenesis in the
recently generated Tipe3 knockout (Tipe3/) mice (Figure S2F).
Under pathogen-free conditions, thesemice developed normally
and did not exhibit noticeable signs of spontaneous diseases
during the first 3 months of their lives (data not shown). However,
following subcutaneous injection with the carcinogen 3-methyl-
cholanthrene, Tipe3/ mice exhibited a markedly delayed skin
tumor onset and reduced tumor size in comparison with wild-
type (WT)mice (Figures 2G and 2H). As expected, Tipe3/ fibro-
sarcoma cells grew much slower than WT controls in the culture
(Figure 2I).
The Unique N-Terminal Region of TIPE3 Is Essential for
Its Effect on Cell Growth and Survival
Unlike other members of the TNFAIP8 family that were capable
of inducing cell death, TIPE3 did not reduce cell viability in the
culture (Figures S2A and S2G). To the contrary, when overex-
pressed in NIH 3T3 cells, TIPE3 was able to increase the per-
centage of S phase cells, even in the absence of the oncogenic
Ras (Figure 3A). Consistent with this observation, TIPE3 drives
cap-dependent protein synthesis required for G1-S transition.
Cotransfection of TIPE3-expressing vector and green fluores-
cence protein (GFP)-expressing vector that contained a cap-
dependent translation initiation site significantly increased theesis
t) and C57BL/6 MEFs (right). Cells were first serum starved for 12 hr and then
being collected for the RNA analyses. The expression levels of TIPE3 in NIH 3T3
f TIPE3 protein expression in tumors and their adjacent normal tissues from
. TIPE3-positive cells are shown in brown (B and D). Quantitation of the TIPE3
and 24 patients with esophageal cancer (E) was performed as described in
ression score of patients. The horizontal bars represent the medians.
sing either shTIPE3 or short hairpin scrambled (shScr) RNA (control) over the
r shTIPE3 or shScr. Numbers of colonies formed by cells expressing shScr were
ents were repeated at least three timeswith similar results. See also Figure S1.
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Figure 2. TIPE3 Promotes Tumorigenesis, Cell Growth, and Cell Survival In Vitro and In Vivo
(A–C) Analyses of cell growth (A), relative colony size in soft agar (B), and cell cycle progression (C) of NIH 3T3-HRasV12 cells stably transfected with either TIPE3-
Flag or empty vector. For (B), number of colonies formed by NIH 3T3-HRasV12 cells transfected with empty vector was set as 1. The experiments were repeated
at least three times with similar results. Values represent means ± SD.
(D–F) TIPE3 promotes tumor growth in a murine xenograft model. Nude mice (n = 14) were injected subcutaneously with NIH 3T3-HRasV12 cells stably
transfected with either TIPE3-Flag or empty vector. (D) Tumor volume was determined over a course of 10 days. (E) At day 10, tumors were excised and
photographed. In vivo cell proliferation was analyzed by BrdU incorporation. (F) The percentages of BrdU-positive cells in tumor sections are shown. Results are
representative of two independent experiments. Values represent means ± SD.
(G–I) Tipe3 deficiency reduces tumor growth in mice. Tipe3/ mice and wild-type (WT) controls (n = 15), 7 weeks of age, were injected subcutaneously with
3-methylcholanthrene. (G) Tumor incidence was examined for up to 17 weeks. Data are pooled from two independent experiments. (H) Tumor volume was
monitored for up to 17weeks. Results are representative of two independent experiments. Values represent means ± SEM; the p values shown are for differences
after week 11. (I) Growth of Tipe3/ andWT fibrosarcoma cells over the indicated times. Data are pooled from three independent Tipe3/ and two independent
WT fibrosarcoma cell cultures established from different 3-methylcholanthrene-induced tumors. The cell numbers at 0 hr were set as 1. The experiments were
repeated four times with similar results.
Values represent means ± SD. *p < 0.05; **p < 0.01. See also Figure S2.
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TIPE3 in Phospholipid Signaling and Cancerexpression of GFP (Figure 3B). The TIPE3 effect was less
apparent in cells transfected with a GFP-expressing vector
that contained an internal ribosome entry site (Figure S3A). The468 Cancer Cell 26, 465–478, October 13, 2014 ª2014 Elsevier Inc.effect of TIPE3 on cap-dependent GFP expression was signifi-
cantly reduced by the PI3K inhibitor LY294002 and/or the
MEK-ERK pathway inhibitor PD98059 (Figure S3B), indicating
Cancer Cell
TIPE3 in Phospholipid Signaling and Cancerthat TIPE3 may play a role in the regulation of the PI3K-AKT and
MEK-ERK signaling pathways.
As stated earlier, TIPE3 overexpression reduced the percent-
age of dying tumor cells in nude mice. In vitro, a similar effect
was observed in cultured NIH 3T3 cells. TIPE3 significantly
decreased serum deprivation-induced death of NIH 3T3 cells,
as assessed by trypan blue staining (Figure 3C) and cleaved
caspase-3 staining (Figure S3C), and the addition of the PI3K
inhibitor LY294002 abolished this effect (Figures S3C and S3D).
All TIPE family proteins contain a highly conserved TIPE2
homology (TH) domain consisting of seven a helices (Fig-
ure S3E) (Zhang et al., 2009). TIPE3 has a unique N-terminal
(NT) sequence of 19 amino acids, designated as the NT region
here, which is not seen in other members of the TIPE family.
Hypothesizing that the TIPE3 NT region is important for its
unique ability to promote cell growth and survival, we investi-
gated the effect of deleting it. A truncated TIPE3 variant lacking
amino acids 2–20 (trTIPE3) not only lost the function of TIPE3 but
also appeared to exert a dominant negative effect. Overexpres-
sion of trTIPE3 significantly reduced cell growth, decreased
the number of S-phase cells, enhanced cell death, and reduced
cap-dependent translation (Figures 3D–3I). The trTIPE3 effect on
serum starvation-induced cell death was not further enhanced
by LY294002, suggesting that trTIPE3 might inhibit the PI3K
pathway (Figure 3F). Notably, when cotransfected into the
same cells, the inhibitory effects of trTIPE3 on cell growth and
death prevailed over those of WT TIPE3, indicating that trTIPE3
may function in a dominant negative fashion (Figures 3J and
3K). It is to be noted that location of the Flag-tag did not affect
TIPE3 functions (Figures 3L and 3M). TIPE2, another member
of the TIPE family that exhibits similar activities as trTIPE3 in
cell growth and death, completely lost its function when fused
to the NT region of TIPE3 (Figures 3L and 3M).
TIPE3 Promotes Activation of the PI3K-AKT and
MEK-ERK Pathways
TIPE3 overexpression in NIH 3T3 cells substantially enhanced
AKT phosphorylation, whereas trTIPE3 overexpression reduced
it, and similar effects were seen for phosphorylation of ERK and
p70S6K (Figure 4A; Figure S4A). Both AKT and ERK regulate
cyclin D1 levels and thus influence cell cycle G1-S transition.
Cyclin D1 levels were elevated in NIH 3T3 cells transfected
with TIPE3 and decreased in cells transfected with trTIPE3
(Figures 4A and S4A). Additionally, TIPE3 enhanced HRasV12-
induced phosphorylation of AKT and ERK in NIH 3T3 cells
(Figures 4A and S4A).
On the other hand, TIPE3 knockdown human NCI-H727 and
T24 carcinomas cells and Tipe3 knockout murine fibrosarcoma
cells showed significantly decreased phosphorylation of both
AKT and ERK (Figure 4B; Figures S4B and S4C). In HT-29 cells,
TIPE3 knockdown impaired AKT activation but did not affect
ERK activation.
To gain more insight into TIPE3-mediated regulation of AKT
and ERK activation, we treated NIH 3T3 cells with PDGF in the
absence or presence of overexpressed TIPE3. PDGF markedly
increased the levels of phosphorylated AKT and ERK, which
were further augmented by TIPE3 (Figures 4C and 4D; Figures
S4D and S4E). The PI3K inhibitor LY294002 completely blocked
AKT phosphorylation, whereas rapamycin that inhibits theCmammalian target of rapamycin had no effect (Figures 4C and
S4D), indicating that TIPE3 amplifies PI3K-dependent activation
of AKT. However, LY294002 did not change the level of ERK
phosphorylation, whereas PD98059, a MEK inhibitor, abolished
ERK phosphorylation entirely, with or without TIPE3 overexpres-
sion. It is interesting that U-73122, an inhibitor of PLC, and bisin-
dolylmaleimide I, an inhibitor of PKC, overpowered the effect of
TIPE3 on ERK phosphorylation (Figures 4D and S4E).
TIPE3 Regulates Phosphoinositide Metabolism and
Signaling
Weobserved significant increases in the total levels of PtdIns(4,5)
P2 inTIPE3-overexpressingcellsusing threeapproaches:protein-
lipid overlay assay with PLCd-Pleckstrin homology (PH) domain
that specifically binds PtdIns(4,5)P2 (Figure 4E), immunofluores-
cence confocal microscopy of fixed cells with anti-PtdIns(4,5)P2
antibody (Figures S4F and S4G), and immunoblotting with an
anti-PtdIns(4,5)P2 antibody (Figure S4H). Similarly, the total pool
of PtdIns(3,4,5)P3 was also markedly increased (4-fold) in
TIPE3-overexpressing cells (Figures 4E and S4H). Consistent
with these results, significant reductions in the PtdIns(4,5)P2
and PtdIns(3,4,5)P3 cellular levels were observed in Tipe3
knockout murine fibrosarcoma cells as compared to WT cells
(Figure S4I). The effect of overexpressed TIPE3 was dependent
on the NT region since the trTIPE3 that lacks it decreased
PtdIns(4,5)P2 and PtdIns(3,4,5)P3 levels (Figure S4J).
To visualize changes in PtdIns(4,5)P2 and PtdIns(3,4,5)P3
levels following stimulation of cells with PDGF, we performed
confocal microscopy of fixed cells using GFP-tagged PH
domains. In untreated NIH 3T3 cells, PLCd-PH-GFP, which
selectively binds PtdIns(4,5)P2, was localized predominantly to
the plasma membrane (Figure 5A; Figure S5A). PDGF stimula-
tion (for 5.5 min) significantly reduced membrane-bound but
increased cytoplasmic PLCd-PH-GFP signals, which is consis-
tent with PI3K- and PLC-induced PtdIns(4,5)P2 depletion.
Remarkably, TIPE3 overexpression significantly increased the
membrane-bound PLCd-PH-GFP signal in both untreated and
PDGF-treated cells, whereas trTIPE3 overexpression greatly
decreased it (Figures 5A and S5A). It is important to note that
TIPE3 overexpression completely eliminated the PDGF-induced
reduction of the membrane-bound PLCd-PH-GFP signal (vector
versus TIPE3 groups), indicating that PtdIns(4,5)P2 depletion
was not significant in the presence of overexpressed TIPE3.
The GRP1 and AKT PH domains selectively bind PtdIns(3,4,5)
P3 and PtdIns(3,4,5)P3/PtdIns(3,4)P2, respectively (Ferguson
et al., 2000). In untreated NIH 3T3 cells, AKT-PH-GFP was local-
ized primarily to the cytoplasm and weakly to the nucleus and
plasma membrane; GRP1-PH-GFP was localized prominently
to the nucleus and weakly to the cytoplasm (Figures 5B and
5C; Figures S5B and S5C). A few minutes after PDGF stimula-
tion, both AKT-PH-GFP and GRP1-PH-GFP showed a notice-
able translocation to the plasma membrane. TIPE3 significantly
increased the levels of plasma membrane-bound AKT-PH-GFP
and GRP1-PH-GFP in both untreated and PDGF-stimulated
cells. These TIPE3 effects were dependent on the NT region
since the trTIPE3 that lacks it had the opposite effects (Figures
5B and 5C; Figures S5B and S5C).
Although slightly concentrated at the plasma membrane,
TIPE3 protein was distributed throughout the cytoplasm ofancer Cell 26, 465–478, October 13, 2014 ª2014 Elsevier Inc. 469
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Figure 3. The NT Region of TIPE3 Is Essential for Its Ability to Promote Cell Growth and Survival
(A) Cell cycle analysis of NIH 3T3 cells stably transfected with either TIPE3-Flag or empty vector.
(B) 293T cells were cotransfected with pEGFP-C3 (50cap-GFP, for cap-dependent translation) and either TIPE3-Flag-expressing or empty vector. The relative
levels of GFP protein expression 32 hr after transfection were quantified by measuring the cellular mean fluorescence intensity (MFI) (left), whereas the relative
levels of GFP mRNA were determined by real-time PCR (right). Protein and mRNA levels of cells transfected with empty vector were set as 1.
(legend continued on next page)
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TIPE3 in Phospholipid Signaling and Canceruntreated cells (Figure 5D; Figures S5A–S5C). On PDGF ac-
tivation, TIPE3 protein translocated from cytoplasm to plasma
membrane, yielding a clear appearance of plasma membrane
localization (Figures 5E and S5A–S5C). No such PDGF-induced
effect was seen for the trTIPE3 protein, although a fraction of the
protein was also localized to the plasma membrane (Figures 5D
and S5A–S5C).
To determine whether altering TIPE3 subcellular localization
changes the phosphoinositide distribution, we fused TIPE3
with GFP to force it to go into the nucleus as previously
described (Seibel et al., 2007). We found that TIPE3 was
excluded from the nucleus, whereas GFP and the TIPE3-GFP
fusion protein were present in the nucleus, indicating that GFP
confers the ability for TIPE3 to enter this organelle (Figures
S5D–S5F). Notably, we observed strong PtdIns(4,5)P2 staining
in the nuclei of all cells expressing TIPE3-GFP but not in those
of cells expressing TIPE3 or GFP alone or in nontransfected cells
(p < 0.0001) (Figures S5D–S5F).
The Crystal Structure of TIPE3 Reveals a Lipid-Binding
Scaffold
To help elucidate the molecular mechanism by which TIPE3
functions, we sought to determine its crystal structure. We crys-
tallized the full-length conserved TH domain, i.e., a trTIPE3 that
lacks amino acids 2–20, in the space group I222 (Protein Data
Bank [PDB] ID: 4Q9V). The structure was determined by molec-
ular replacement, and the atomic model was refined at 2.3 A˚
resolution (Figure 6A; Table S1).
The structure of the crystallized TIPE3 consists of an NT a0
helix and six additional helices (a1–a6) that are similar to those
observed for TIPE2 (residues 24–184; PDB ID: 3F4M) (Zhang
et al., 2009). The helices a1–a6 of TIPE3 can be aligned to those
of TIPE2 with a root-mean-squared deviation (RMSD) of 0.574 A˚
over 128 aligned Ca atoms (Figure 6B). The most prominent
feature of the TH fold is the presence of a large centrally located
hydrophobic cavity (Figure 6C), which, with 20 A˚ in depth and
10 A˚ in diameter, was thought to be the binding site for a lipo-
philic molecule. Similar to TIPE2 (Zhang et al., 2009), the hydro-
phobic cavity in TIPE3 is occupied by two tubes of electron
density (each measuring approximately 20 A˚ in length), which(C) NIH 3T3 cells stably transfected with either TIPE3-Flag or empty vector wer
assessed by trypan blue staining.
(D) Cell growth of NIH 3T3 cells stably transfected with either trTIPE3-Flag or em
(E) Relative numbers of 293T cells transfected with the indicated amounts of trT
Number of 293T cells transfected with 0.5 mg of empty vector was set as 1.
(F) NIH 3T3 cells stably transfected with either trTIPE3-Flag or empty vectors were
times. Cell death was assessed by trypan blue staining.
(G) Cell death of 293T cells transfected with the indicated amounts of trTIPE3-Fl
(H) Cell cycle analysis of NIH 3T3 cells stably transfected with either trTIPE3-Fla
(I) 293T cells were cotransfected with pEGFP-C3 and either trTIPE3-Flag-expres
transfection were quantified by measuring cellular MFI, whereas the relative levels
mRNA levels of cells transfected with empty vector were set as 1.
(J and K) 293T cells were cotransfected with equal amounts (2 mg) of the follo
expressing vectors. Relative cell numbers were determined (J), and the degree
number of 293T cells transfected with empty vector was set as 1.
(L and M) 293T cells were transfected with one of the following plasmids as i
NT-TIPE3-TIPE2-Flag (TIPE2-Flag fused with the NT region of TIPE3). Relative ce
by trypan blue staining 32 hr later. For (L), the number of 293T cells transfected
The y axis values represent means ± SD. *p < 0.05; **p < 0.01; ns, not significant. T
with similar results. See also Figure S3.
Care connected at the surface opening of the cavity (Figure 6D).
The shape and size of the electron density are reminiscent of
two aliphatic tails of a phospholipid, although the head group
cannot be identified because of poor electron density. Notably,
positive ion electrospray ionization mass spectrometry of lipids
copurified with trTIPE3 from bacteria revealed two major peaks:
653 mass-to-charge ratio and 683 mass-to-charge ratio. The
molecular mass of the first peak is indicative of 16:0/16:1 phos-
phatidic acid (PA), whereas that of the second peak is indicative
of 16:0/18:0 or 16:0/18:1 PA. Therefore, it is likely that PAs are
the phospholipids that occupy the hydrophobic cavity of trTIPE3
expressed in bacteria (which do not possess phosphoinositides).
Within the same asymmetric unit, helix a0 from one TIPE3
molecule forms a coiled coil with that of another TIPE3molecule,
constituting a homodimer (Figure S6A). These two a helices
interact with each other mainly through van der Waals contacts.
In addition, the a0 helix from one TIPE3 molecule also interacts
with the a1 helix of its partner molecule. Notably, truncation of
the a0 helix exhibits no significant effect on the elution profile
of TIPE3 on gel filtration, suggesting that the observed TIPE3
dimer is likely an artifact of crystallization at high protein
concentrations.
TIPE3 Binds to Phosphoinositides through Its TH
domain, and This Binding Is Essential for Its Function
Next, we examined whether affinity-purified TIPE3 exhibits any
binding specificity for the various eukaryotic lipid molecules
in the protein-lipid overlay assay (Figures S6B–S6D). Of the
22 different types of eukaryotic lipids tested, TIPE3 appeared
to predominantly interact with PtdIns(4,5)P2, PtdIns(3,5)P2,
PtdIns(3,4)P2, PtdIns4P, PtdIns(3,4,5)P3, and PA (Figures S6C
and S6D; data not shown). The trTIPE3, as well as TIPE2,
TIPE1, and TNFAIP8 proteins, interacted with the same set of
lipids, indicating that the highly conserved TH domain, but not
the NT region, is responsible for the observed lipid binding activ-
ity (Figures S6B, S6C, and S6E). By contrast, the PLCd-PH
domain (GST-PLCd-PH) interacted only with PtdIns(4,5)P2 in
the same assay (Figure S6C). PLCd-PH binds to the PtdIns(4,5)
P2 head group, and addition of 15 mM free Ins(1,4,5)P3 to the
overlay assay was sufficient to prevent PLCd-PH binding toe cultured in serum-free medium for the indicated times, and cell death was
pty vectors over indicated times.
IPE3-Flag plasmid or empty vector were determined 32 hr after transfection.
cultured in serum-freemediumwith or without LY29 (LY29004) for the indicated
ag plasmid or empty vector were assessed by trypan blue staining.
g or empty vectors.
sing or empty vectors. The relative levels of GFP protein expression 16 hr after
of the GFP mRNA expression were determined by real-time PCR. Protein and
wing plasmids as indicated: empty, TIPE3-Flag-expressing, or trTIPE3-Flag-
of cell death (K) was assessed by trypan blue staining 32 hr later. For (J), the
ndicated: empty vector, TIPE3-Flag, trTIPE3-Flag, Flag-trTIPE3, TIPE2-Flag,
ll numbers were determined (L), and the degree of cell death (M) was assessed
with empty vector was set as 1.
he experiments were performed in duplicates and repeated at least three times
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Figure 4. TIPE3 Promotes the Activation of PI3K-AKT and MEK-ERK Pathways
(A) Whole cell lysates were prepared fromNIH 3T3 cells stably transfected with TIPE3-Flag, trTIPE3-Flag, or empty vectors (left andmiddle panels), or TIPE3-Flag
and/or HRasV12 vectors (right panel). Western blot (WB) was performed using antibodies against the indicated proteins. The densitometric quantification of
protein signals was made using ImageJ software. Signals of cells transfected with empty vector were set as 1.
(B) Whole cell lysates were prepared fromNCI-H727, T24, and HT-29 cells stably expressing either shTIPE3 or small hairpin scrambled (shScr). Western blot (WB)
was performed using antibodies against the indicated proteins. Signals of cells treated with shScr were set as 1.
(C and D) NIH 3T3 cells stably transfected with either TIPE3-Flag or empty vectors were serum starved and then stimulated with 40 ng/ml of PDGF for the
indicated times, with or without the following inhibitors: LY29 (LY29004), Rapa (Rapamycin), PD98 (PD98059), Bis I (Bisindolylmaleimide I), or U-73 (U-73122). (C)
pertains to p-AKT, and (D) pertains to p-ERK. Lysates of these cells were used for western blot with antibodies against the indicated proteins. Signals of cells
transfected with vector 2.5 min after PDGF stimulation were set as 1.
(E) Cellular levels of PtdIns(4,5)P2 and PtdIns(3,4,5)P3 in NIH 3T3 cells stably transfected with either TIPE3-Flag or empty vector were estimated by protein-lipid
overlay assay with GST-PLCd-PH and GST-GRP1-PH domains as described in Supplemental Experimental Procedures. Signals of cells transfected with empty
vector were set as 1.
The y axis values represent means ± SD. *p < 0.05, and **p < 0.01; ns, denotes not significant. The abbreviation p- indicates phosphorylated. The experiments
were performed at least three times with similar results. See also Figure S4.
Cancer Cell
TIPE3 in Phospholipid Signaling and Cancernitrocellulose-bound PtdIns(4,5)P2 (Figure S6C). However, add-
ing free Ins(1,4,5)P3 had no effect on TIPE3 binding to PtdIns(4,5)
P2, suggesting that the mode of interaction is different from that472 Cancer Cell 26, 465–478, October 13, 2014 ª2014 Elsevier Inc.between PLCd-PH and PtdIns(4,5)P2 (Figure S6C). This is
consistent with our structural data, which identify an anchoring
role for the acyl chains of phospholipid (Figure 6D).
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Figure 5. TIPE3 Regulates Lipid Metabolism and Signaling
(A–C) NIH 3T3 cells were cotransfected with PLCd-PH-GFP (A), AKT-PH-GFP (B), or GRP1-PH-GFP (C) and one of the following plasmids as indicated: pRK5
vector (vector), pRK5-TIPE3-Flag (TIPE3), and pRK5-trTIPE3-Flag (trTIPE3). Thirty-two hours after the transfection, cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) with 10% fetal calf serum (DMEM10, in A through C) or in DMEM10 with 40 ng/ml of PDGF for 5.5 min (+PDGF in A), or they were serum
starved for 4 hr and then cultured in DMEM containing 40 ng/ml of PDGF for 7.5 min (+PDGF in B and C) followed by fixation. Cells expressing the Flag-tagged
proteins were selected by immunofluorescencemicroscopywith an anti-Flag antibody. Ratios of GFP fluorescence intensity on plasmamembrane (PM) over that
in the cytoplasm (Cyt) of the same cells are calculated based on line fluorescence intensity profiles.
(D) Membrane (M) and cytoplasmic (Cyt) proteins fractions were prepared from NIH 3T3 cells stably transfected with TIPE3-Flag and trTIPE3-Flag. Western blot
(WB) was performed using antibodies against the indicated proteins. Signals of TIPE3 or trTIPE3 in membrane fractions were set as 1.
(E) NIH 3T3 cells stably transfected with TIPE3-Flag were cultured in DMEM with 10% of FCS (DMEM10) or serum-starved for 4 hr and then cultured in DMEM
containing 40 ng/ml of PDGF for 7.5 min (+PDGF). Membrane protein fractions (M) of these cells were analyzed by western blot (WB) using antibodies against the
indicated proteins. Signals of TIPE3 in membrane fractions of cells cultured in DMEM10 were set as 1.
Values represent means ± SD; **p < 0.01. The experiments were repeated at least three times with similar results. See also Figure S5.
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TIPE3 in Phospholipid Signaling and CancerTo test the importance of the hydrophobic cavity in the TIPE3
TH domain, we replaced leucine 60, positioned in the center of
this pocket, with the much bulkier tryptophan to yield the
TIPE3 60W mutant (Figure S7A). A similar approach was
described to test the importance of the hydrophobic cavity in
orphan nuclear hormone receptors hypothesized to bind phos-
phoinositides (Krylova et al., 2005; Sablin et al., 2003). TIPE3
60Wmutant showed markedly reduced ability to bind phosphoi-
nositide (Figure S7B). This finding is consistent with the struc-
ture-based proposition that the acyl chains of phosphoinositide
are positioned inside the TH domain cavity, allowing the nega-
tively charged head group to form electrostatic interactions
with the neighboring positively charged side chains that line
the opening of the cavity (Figures 6C and 6D). Supporting this
analysis, a TIPE3 4Q mutant (in which lysines 33, 34, 38, and
42 were all replaced with glutamines) and a TIPE3 2Q mutant
(in which arginines 93 and 109 were replaced with glutamines)
both exhibited marked reductions in phosphoinositide bindingC(Figures S7A and S7B). By contrast, a TIPE3 3Q mutant—in
which glutamine replaces lysines 76, 79, and 83, which lie on a
positively charged surface distant from the cavity opening—
showed WT levels of phosphoinositide binding in the overlay
assay (Figures S7A and S7B).
Notably, the TIPE3 mutants that showed impaired phosphoi-
nositide binding also had markedly reduced TIPE3 functions.
Compared with WT TIPE3, the TIPE3 60W, 2Q, and 4Q
mutants had significantly reduced capacities to promote cap-
dependent translation of GFP (Figure S7C), whereas TIPE3 3Q
(which retains phosphoinositide binding) did not—although all
mutants were expressed at similar levels as those of the WT
TIPE3 (Figures S7C and S7D). As expected, TIPE3 4Q had no
detectable effects on ERK activation or PtdIns(4,5)P2 levels
and might even reduce the levels of AKT phosphorylation and
PtdIns(3,4,5)P3 (Figures S7E and S7F). Introduction of a
4Q-equivalent mutation in trTIPE3 abolished its ability to bind
phosphoinositide (Figure S7B). Moreover, 4Q, 2Q, and 60Wancer Cell 26, 465–478, October 13, 2014 ª2014 Elsevier Inc. 473
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Figure 6. The Crystal Structure of the TH-Domain of Human TIPE3
(A) Cartoon presentation of TH-domain of human TIPE3 (trTIPE3, residues 21–204). Helices are rainbow colored with a0 in blue and a6 in red.
(B) Cartoon representation of superposition of human TIPE3 (residues 21–204, shown in green) with the human TIPE2 (residues 24–184, shown in red) structures.
(C) TIPE3 contains a centrally located hydrophobic cavity. (Left) TIPE3 is shown in a green cartoon representation; amino acids with hydrophobic side chains that
line the cavity are shown in orange. (Right) TIPE3 eletrostatic surface potential: blue, positive; red, negative.
(D) TIPE3 is shown in a green cartoon representation. The two long connected tubes of 2Fo-Fc electron density found in TIPE3 cavity is shown in blue mesh,
contoured at 1.5 s.
See also Table S1 and Figure S6.
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TIPE3 in Phospholipid Signaling and Cancermutations in trTIPE3 reduced its ability to inhibit cell proliferation
and to induce cell death (Figures S7G–S7I), whereas the 3Q
mutation had no such effect.
TIPE3 Can Act as a PtdIns(4,5)P2 and PtdIns(3,4,5)P3
Transfer Protein
Although the TH fold is unique, the lipid-binding mode by the
TIPE family of proteins is reminiscent of lipid-binding mode
by lipid transfer proteins (Prinz, 2010). We wondered whether
phosphoinositide-loaded TIPE3 might exert its effects in part
by transferring phosphoinositides to the plasma membrane
and whether the dominant negative trTIPE3 might promote
cell death by reducing the membrane pool of PtdIns(4,5)P2 and
PtdIns(3,4,5)P3. Consistent with this notion, trTIPE3-induced
cell death could be partially reversed by overexpressing a myris-
toylated variant of phosphatidylinositol-4-phosphate 5-kinase
(PIP5K) that leads to elevated plasma membrane PtdIns(4,5)P2
(Figure S7J) (Volpicelli-Daley et al., 2010; Wang et al., 2008).
Neither a constitutively active PI3K (PI3KCAE545) nor HRasV12
had any detectable effect on trTIPE3-induced cell death
(Figure S7J).
To determine whetherWT TIPE3 protein might have properties
consistent with a phosphoinositide transfer protein, we exam-
ined whether it could recognize PtdIns(4)P, PtdIns(4,5)P2, and
PtdIns(3,4,5)P3 present in a lipid bilayer, and extract the lipid474 Cancer Cell 26, 465–478, October 13, 2014 ª2014 Elsevier Inc.from the membrane. We purified recombinant TIPE3 and TIPE3
4Q from mammalian cells (Figure S6B) and assessed their
binding to small unilamellar vesicles (SUVs) containing 100%
phosphatidylcholine (PC), 10% PtdIns(4)P, 10% PtdIns(4,5)P2,
or 10% PtdIns(3,4,5)P3 in a PC background using a well-estab-
lished centrifugation-based assay (Kavran et al., 1998; Lee
and Lemmon, 2001). TIPE3 sedimented efficiently with vesicles
containing 10% phosphoinositides, with the following order of
preference: PtdIns(3,4,5)P3 > PtdIns(4,5)P2 > PtdIns(4)P (Figures
7A and 7B). Consistent with the results of the overlay assay,
TIPE3 4Q showed significantly reduced binding to PtdIns(4,5)
P2- and PtdIns(3,4,5)P3-containing vesicles compared with WT
TIPE3; more than 60% of the 20 mM TIPE3 and only 30%
of 20 mM TIPE3 4Q were bound to vesicles when the concentra-
tion of vesicles was 1,000 mM (Figures 7A and 7B). Lack of bind-
ing specificity of TIPE3 4Q to PtdIns(4)P-, PtdIns(4,5)P2-, and
PtdIns(3,4,5)P3-containing vesicles suggests that lysines in
the a0 helix may form electrostatic interactions with 5- and
3-phosphate groups of PtdIns(4,5)P2 and PtdIns(3,4,5)P3. By
contrast, only background levels of TIPE3 and TIPE3 4Q sedi-
mented with 100% PC vesicles. A negative control protein
(trypsin inhibitor) showed no binding to either type of vesicles
(Figures 7A and 7B).
Having established that TIPE3 could bind to vesicles con-
taining PtdIns(4,5)P2, we next asked whether the protein could
Cancer Cell
TIPE3 in Phospholipid Signaling and Cancerextract fluorescently labeled phosphoinositide from these vesi-
cles and effectively solubilize it. When increasing concentrations
of TIPE3 were incubated for 1 hr with 100 mM vesicles containing
20% TopFluor PtdIns(4,5)P2 and 80% PC, substantial amounts
of TopFluor PtdIns(4,5)P2 fluorescence was detected in the
supernatant after ultracentrifugation, whereas equivalent exper-
iments with the PLCd-PH domain showed no significant fluores-
cence in the supernatant (Figures 7C and S6B). This result
suggests that TIPE3 can effectively remove PtdIns(4,5)P2 from
the vesicles and solubilize it in the aqueous phase—extracting
up to 50% of the total available PtdIns(4,5)P2 at a protein con-
centration of 40 mM. Size exclusion chromatographic analysis
of the supernatants revealed a single peak corresponding to
TIPE3 monomer, ruling out the possibility that TIPE3/vesicle
complexes remain in the supernatants (data not shown). Sup-
porting its dominant negative effect, trTIPE3 did not remove
TopFluor PtdIns(4,5)P2 after binding to 20% TopFluor
PtdIns(4,5)P2-containing vesicles; 10% of 20 mM trTIPE3 re-
mained in supernatant (Figure S7K). Similar to trTIPE3, TIPE2
strongly bound to vesicles containing 20% PtdIns(4,5)P2 and
80% PC, with only 15% remaining unbound (data not shown).
It is important to note that neither TIPE3 nor TIPE3 4Qwas able to
bind and extract TopFluor PC from 100 mM vesicles containing
20% TopFluor PC and 80% PC used as control (Figure S7K).
We further investigated the ability of TIPE3 to extract
PtdIns(4,5)P2 from membranes using a surface plasmon reso-
nance (SPR)-based assay. PtdIns(4,5)P2-containing vesicles
(3% and 10%) were immobilized on L1 sensor chips, and the
binding signal obtained with a saturating injection of PLCd-PH
was measured before and after TIPE3 or TIPE3 4Q had been
flowed over the sensor chip. A significant reduction (more than
60%) in PLCd-PH binding at saturation was detected after
TIPE3 had been exposed to the sensor chip (Figure 7D), indi-
cating that TIPE3 extracts PtdIns(4,5)P2 from the immobilized
vesicles. TIPE3 4Q also appeared to extract PtdIns(4,5)P2 from
the immobilized membranes, but to a reduced extent, which is
consistent with our other studies of this mutant (Figure 7D).
As discussed earlier, TIPE3 overexpression appears to in-
crease both total and plasma membrane levels of PtdIns(4,5)P2
in NIH 3T3 cells. To determine whether TIPE3 is capable of in-
serting extracted PtdIns(4,5)P2 into a lipid bilayer, we analyzed
transfer of TopFluor PtdIns(4,5)P2 from the soluble TIPE3/
TopFluor PtdIns(4,5)P2 complexes detected in the supernatant
in Figure 7C to 100% PC vesicles. We collected supernatants
frommixtures of TIPE3 with 100 mMTopFluor PtdIns(4,5)P2-con-
taining vesicles that had been subjected to ultracentrifugation
and incubated them with vesicles containing 250 mM 100% PC
for 1 hr at room temperature. The mixtures were then recentri-
fuged as described elsewhere (Lee and Lemmon, 2001), and
the level of TopFluor PtdIns(4,5)P2 fluorescence remaining in
the supernatant was measured. Addition of vesicles containing
100% PC alone led to a substantial reduction in fluorescence
corresponding to presumed TIPE3/TopFluor PtdIns(4,5)P2 com-
plexes in the supernatant (Figure 7E). This was accompanied by
a dramatic increase in fluorescence intensity associated with the
vesicle pellet (Figure 7F), indicating that TopFluor PtdIns(4,5)P2
was transferred into the PC vesicles. The concomitant loss of
TopFluor PtdIns(4,5)P2-derived fluorescence from the superna-
tant and its acquisition in the pellet was not accompanied byCany change in TIPE3 protein concentrations in the supernatant,
arguing that TIPE3 has transferred the labeled PtdIns(4,5)P2 to
the PC vesicles (Figure 7E).
TIPE3 Can Promote the Generation of PtdIns(3,4,5)P3
by PI3K
To examine whether TIPE3 could promote the phosphorylation
of PtdIns(4,5)P2 by PI3K(p110a/p85a), we performed in vitro
membrane capture (enzymatic) assay for the PI3K in the absence
or presence of increasing amounts of TIPE3 (Knight et al., 2007).
SUVs containing 10% PtdIns(4,5)P2 in a PC background were
used in this assay. We found that TIPE3 indeed stimulated
PI3K activity in a concentration-dependent manner (Figure 7G).
At 20min after the initiation of the PI3K assay, we observed three
times more PtdIns(3,4,5)P3 in reactions containing 200 nM
TIPE3, two times more PtdIns(3,4,5)P3 in reactions containing
100 nM TIPE3, and 1.65 times more PtdIns(3,4,5)P3 in reactions
containing 20 nM TIPE3 than those of control PI3K reactions
lacking TIPE3 (BSA was used as a control protein). Finally, we
examined whether TIPE3 associated with PI3K. We immunopre-
cipitated endogenous p110a, p110b, and p85 fromNIH 3T3 cells
overexpressing TIPE3, with or without PDGF treatment, and
found that TIPE3 did not coimmunoprecipitate with these PI3K
proteins. In addition, we did not detect an association of TIPE3
with the oncogenic mutant of p110a, E545K, when both proteins
were overexpressed in 293T cells.
DISCUSSION
PtdIns transfer proteins (PITPs) play essential roles in phospho-
lipid signaling, and their dysregulation leads to a variety of disor-
ders, including cancer and degenerative diseases (Nile et al.,
2010). It is unclear whether, and to what degree, currently known
PITPs or PITP-like proteins can transfer phosphoinositides. It
was reported that the yeast Kes1/Osh4p protein (de Saint-
Jean et al., 2011) and the human a-TTP protein (Kono et al.,
2013) that belongs to the Sec14-like family might transfer
PtdIns4P and PtdIns(4,5)P2, respectively, but not other phos-
phoinositides. The mammalian nuclear receptor SF-1 and
LRH-1 proteins of the NR5A family were also found to accommo-
date phosphoinositides within their large hydrophobic cavities
(Krylova et al., 2005), but whether they can transfer these lipids
is unknown.
The results reported here argue that the TH domain of TIPE
proteins can function as a lipid transfer domain and that TIPE3
is a lipid transfer protein for two second messengers,
PtdIns(4,5)P2 and PtdIns(3,4,5)P3. Crystal structure and muta-
genesis analyses revealed that the acyl chains of lipid are likely
accommodated in the hydrophobic cavity formed by the a1–a6
helixes of the TIPE3 TH domain. The negatively charged head
group of phosphoinositides is likely involved in electrostatic in-
teractions with positively charged amino acids of the a0 helix
(that might function as a flexible ‘‘lid’’) and those located at the
entrance to the hydrophobic cavity. Structure determination of
the full-length TIPE3 bound to phosphoinositides is required to
provide additional insight into this issue.
Our results support a dual role model for TIPE3 in phosphoino-
sitide signaling and metabolism. TIPE3 may regulate the spatial
and temporal distribution of lipid second messengers inancer Cell 26, 465–478, October 13, 2014 ª2014 Elsevier Inc. 475
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Figure 7. TIPE3 Is a Phosphoinositide Transfer Protein
(A and B) The sedimentation-based binding assay was used to determine the percentages of TIPE3, TIPE3 4Q, and control protein trypsin inhibitor (Trypsin in)
bound to vesicles containing 10% PtdIns(4)P + 90% PC (10% PtdIns(4)P); 10% PtdIns(3,4,5)P3 + 90% PC (10% PtdIns(3,4,5)P3); 10% PtdIns(4,5)P2 + 90% PC
(10%PtdIns(4,5)P2); or 100%PC as indicated. (A) Binding with 1,000 mMconcentration of total lipid; (B) binding with varying concentrations of total lipid. Proteins
were used at a concentration of 20 mM.
(C) The sedimentation-based extraction assay was used to determine the percentages of TopFluor PtdIns(4,5)P2 extracted from 100 mM 20% TopFluor
PtdIns(4,5)P2 + 80%PC vesicles and transferred to supernatant by TIPE3 and PLCd-PH (left panel); and fractions of TIPE3 and PLCd-PH proteins not bound to the
20% TopFluor PtdIns(4,5)P2 + 80% PC vesicles (right panel).
(D) In the SPR-based assay, 3% (left panel) and 10% (right panel) PtdIns(4,5)P2-containing vesicles were immobilized on L1 sensor chips, and the binding signal
obtained with a saturating injection of GST-PLCd-PH (5 mM) was measured before and after TIPE3 or TIPE3 4Q (both at 40 mM) had been flowed over the sensor
chip. GST-PLCd-PH binding to PtdIns(4,5)P2-containing surfaces before TIPE3 or TIPE3 4Q exposure is set as 100%, and GST-PLCd-PH binding to PtdIns(4,5)
P2-containing surfaces after TIPE3 or TIPE3 4Q exposure is presented as the percentage reduction.
(E) The sedimentation-based transfer assay was used to measure the depletion of TopFluor PtdIns(4,5)P2 from soluble TIPE3-TopFluor PtdIns(4,5)P2 in
supernatants (left panel) and fractions of TIPE3 remaining in supernatants (right panel) after incubation with 100% PC vesicles or buffer alone.
(legend continued on next page)
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PtdIns(4,5)P2 and PtdIns(3,4,5)P3 from the lipid bilayer and shut-
tling them through the aqueous phase. Additionally, TIPE3 may
also function as a lipid-presenting protein to enhance the activity
of phosphoinositide-modifying enzymes such as PI3K. A similar
function has been reported for PtdIns transfer proteins such as
Sec14, the major yeast PITP protein that regulates phosphoino-
sitide signaling and metabolism by presenting PtdIns to PI4K
(Bankaitis et al., 2010; Lev, 2010; Prinz, 2014; Schaaf et al.,
2008). Consistent with this view, TIPE3 physically translocates
from cytoplasm to plasma membrane on cell activation by
PDGF or on cell transformation by the oncogenic HRasV12
(data not shown). Upregulation of TIPE3 expression in PDGF-
stimulated cells and cancer cells may positively feed back to
cell activation through the aforementioned mechanism.
The TIPE3 TH domain is highly homologous to TH domains of
other members of the TIPE family. The domain is also highly
conserved through evolution and is found in vertebrates; inverte-
brates such as the mosquito and fruit fly; and unicellular eukary-
otes such as choanoflagellate, Dictyostelium, and Entamoeba.
This raises the question as to whether all TH domains are
involved in regulating lipid signaling. Our studies indicate that
all murine TIPE family proteins bind phosphoinositides, and, in
addition to TIPE3, TIPE2 regulates the PtdIns(3,4,5)P3 signaling
pathway. However, the functions of TH domains may be regu-
lated by other sequences present in the protein. For example,
as reported here, the TIPE3 NT region, which is not shared by
other members of the family, is essential for the effects seen
on cell growth and survival; TIPE3 lacking the NT region func-
tions in a dominant negative fashion. Similarly, some TH-con-
taining proteins of the unicellular eukaryotes possess NT PH
domains, which likely affect their functions. Therefore, TH-con-
taining proteins may play diverse roles depending on the non-
TH sequences that they also possess. Thus, despite their high
sequence homology in the TH domains, TIPE2 and TIPE3 appear
to play distinct roles. TIPE2 functions as a negative regulator of
neoplastic cell growth, and its expression is downregulated dur-
ing liver carcinogenesis. The tumor suppressor activity of TIPE2
is likely dependent on its interaction with Rac1 and Rgl/RalGDS
molecules (Gus-Brautbar et al., 2012; Wang et al., 2012). How-
ever, no such interaction could be found for TIPE3 (data not
shown). Therefore, TIPE2 and TIPE3 appear to have distinct
molecular mechanisms.
Hyperactivation of PtdIns(3,4,5)P3 signaling is reported in
more than 50% of human cancers. Somatic gene mutations of
the signaling molecules such as PTEN and PI3K are found in
many of these cancers. Our findings reveal a mechanism of
hyperactivating PtdIns(3,4,5)P3 signaling pathway in cancer
cells by TIPE3, a phosphoinositide transfer protein. Therefore,
TIPE3 may represent a therapeutic target for treating malignant
diseases.(F) The sedimentation-based transfer assaywas used tomonitor the transfer of To
to 100% PC vesicles.
(G) Time course of PI3K (p110a/p85a)-mediated phosphorylation of PtdIns(4,5)P2
PtdIns(3,4,5)P3 were measured by protein-lipid overlay assay with GST-GRP1-PH
1. FIU, fluorescence intensity units; RU, resonance units. Values represent mean
For (A)–(F), the experiments were repeated at least three times with similar results
with similar results. See also Figure S7.
CEXPERIMENTAL PROCEDURES
Mice
Male athymic nude mice (nu/nu) and WT C57BL/6 mice were purchased from
Jackson Laboratories. Tipe3+/ C57BL/6 mice (Tnfaip8l3tm1a(KOMP)Mbp) were
purchased from the Knockout Mouse Project Repository. Mice were housed
in the University of Pennsylvania Animal Care Facilities under pathogen-free
conditions. All animal procedures were preapproved by the Institutional Animal
Care and Use Committee of the University of Pennsylvania, and all experi-
ments conform to the relevant regulatory standards.
Human Samples
Human non-small cell lung cancer arrays containing 60 tumor samples and
their corresponding adjacent normal tissues, as well as human esophageal
carcinoma arrays containing 24 tumor samples and their adjacent normal tis-
sues, were purchased from Outdo Biotech. Human colon cancer and cervical
cancer microarrays were purchased from Xi’an Alena Biotech. All samples
have been deidentified prior to analysis and are therefore considered exempt.
All human study procedures were preapproved by the Institutional Review
Board of Shandong University.
Crystallization, Data Collection, and Structure Determination
The human trTIPE3 (residues 21–204) was purified as described in Supple-
mental Experimental Procedures. Crystals of trTIPE3 were grown at 18C us-
ing the hanging-drop vapor diffusion method by mixing 1 ml of protein
(10 mg/ml in 25 mM Tris-HCl, 1 M NaCl, pH 8.0) with 1 ml of reservoir solution
(0.1 MMES 6.7, 1.95 M (NH4)2SO4). The crystals appeared in 2 days and grew
to full size in a week. The 2.3 A˚ native data were collected at Shanghai Syn-
chrotron Radiation Facility beamline BL17U. The data sets were integrated
and scaled using the HKL2000 package. Further processing was performed
using the CCP4 suite. The structure was solved by molecular replacement us-
ing PHASER and manually refined with COOT and PHENIX. Data collection
and refinement statistics are listed in Table S1. All the figures were prepared
using PyMOL software.
Other experimental procedures, including in vivo tumorigenesis studies;
human tumor studies; cell culture; protein purification; protein crystallization;
protein-lipid overlay assay; and phosphoinositide binding, extraction, and
transfer assays are available in Supplemental Information.ACCESSION NUMBERS
The TIPE3 structure data were deposited in the PDB with the ID code of 4Q9V.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.ccr.2014.07.025.
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